These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 15712103)

  • 21. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.
    McKinnon PS; Paladino JA; Schentag JJ
    Int J Antimicrob Agents; 2008 Apr; 31(4):345-51. PubMed ID: 18313273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activities of various antibiotics, alone and in combination with colistin methanesulfonate, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients.
    Güzel CB; Gerçeker AA
    Chemotherapy; 2008; 54(2):147-51. PubMed ID: 18322363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pseudomonas aeruginosa bloodstream infections: how should we treat them?
    van Delden C
    Int J Antimicrob Agents; 2007 Nov; 30 Suppl 1():S71-5. PubMed ID: 17698326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium.
    Mesaros N; Nordmann P; Plésiat P; Roussel-Delvallez M; Van Eldere J; Glupczynski Y; Van Laethem Y; Jacobs F; Lebecque P; Malfroot A; Tulkens PM; Van Bambeke F
    Clin Microbiol Infect; 2007 Jun; 13(6):560-78. PubMed ID: 17266725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beta-lactam and aminoglycoside resistance rates and mechanisms among Pseudomonas aeruginosa in French general practice (community and private healthcare centres).
    Dubois V; Arpin C; Dupart V; Scavelli A; Coulange L; André C; Fischer I; Grobost F; Brochet JP; Lagrange I; Dutilh B; Jullin J; Noury P; Larribet G; Quentin C
    J Antimicrob Chemother; 2008 Aug; 62(2):316-23. PubMed ID: 18467306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Report: prevalence and resistance pattern of Pseudomonas aeruginosa against various antibiotics.
    Khan JA; Iqbal Z; Rahman SU; Farzana K; Khan A
    Pak J Pharm Sci; 2008 Jul; 21(3):311-5. PubMed ID: 18614431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Empiric therapy for gram-negative pathogens in nosocomial and health care-associated pneumonia: starting with the end in mind.
    Arnold A; Brouse SD; Pitcher WD; Hall RG
    J Intensive Care Med; 2010 Sep; 25(5):259-70. PubMed ID: 20622257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Five-year report of national surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolated from non-tertiary care hospitals in Korea (2002-2006).
    Yoo J; Sohn ES; Chung GT; Lee EH; Lee KR; Park YK; Lee YS
    Diagn Microbiol Infect Dis; 2008 Mar; 60(3):291-4. PubMed ID: 18068936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
    Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia.
    Drusano GL; Preston SL; Fowler C; Corrado M; Weisinger B; Kahn J
    J Infect Dis; 2004 May; 189(9):1590-7. PubMed ID: 15116294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro and in vivo potency of polymyxin B against IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa.
    Miyajima Y; Hiramatsu K; Mizukami E; Morinaga R; Ishii H; Shirai R; Kishi K; Tokimatsu I; Saikawa T; Kadota J
    Int J Antimicrob Agents; 2008 Nov; 32(5):437-40. PubMed ID: 18715759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Mechanisms of pandrug-resistance of Pseudomonas aeruginosa].
    Shen JL; Zhu DM; Wang MG
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(26):1859-62. PubMed ID: 19040025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program.
    Ellis JM; Kuti JL; Nicolau DP
    Clin Ther; 2005 Nov; 27(11):1820-30. PubMed ID: 16368453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aminoglycoside adaptive resistance.
    Karlowsky JA; Zelenitsky SA; Zhanel GG
    Pharmacotherapy; 1997; 17(3):549-55. PubMed ID: 9165557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Investigation of the effect of efflux pump inhibitors to MIC values of ciprofloxacin in clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus].
    Cetinkaya E; Coban AY; Durupinar B
    Mikrobiyol Bul; 2008 Oct; 42(4):553-61. PubMed ID: 19149076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal antibiotic dosing. The pharmacokinetic-pharmacodynamic interface.
    Reed MD
    Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):17-24. PubMed ID: 19667545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple genotypic changes in hypersusceptible strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients do not always correlate with the phenotype.
    Wolter DJ; Black JA; Lister PD; Hanson ND
    J Antimicrob Chemother; 2009 Aug; 64(2):294-300. PubMed ID: 19468029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes.
    Hsu DI; Okamoto MP; Murthy R; Wong-Beringer A
    J Antimicrob Chemother; 2005 Apr; 55(4):535-41. PubMed ID: 15728150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In-vivo impact of the MexXY efflux system on aminoglycoside efficacy in an experimental model of Pseudomonas aeruginosa pneumonia treated with tobramycin.
    Martha B; Croisier D; Durand D; Hocquet D; Plesiat P; Piroth L; Portier H; Chavanet P
    Clin Microbiol Infect; 2006 May; 12(5):426-32. PubMed ID: 16643518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Optimization of antibiotics in combination].
    Zhang LH; Wang LF; Meng ZY; Yu QP; Gao BQ; Ba T; Wang XD; Ma WH; Li YY; Zhang J
    Zhonghua Shao Shang Za Zhi; 2008 Apr; 24(2):93-6. PubMed ID: 18785405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.